Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Claret

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Mathematical Biosciences|April 1, 1996
Nonparametric density estimation applied to population pharmacokineticsL Claret, A Iliadis
Journal of Molecular Biology|October 31, 2000
Functions of the subunits in the FlhD(2)C(2) transcriptional master regulator of bacterial flagellum biogenesis and swarmingL Claret, C Hughes
Journal of Bacteriology|January 14, 2000
Rapid turnover of FlhD and FlhC, the flagellar regulon transcriptional activator proteins, during Proteus swarmingL Claret, C Hughes
Clinical Pharmacology and Therapeutics|July 22, 2009
On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate phase II studiesR Bruno, L Claret
Clinical Pharmacology and Therapeutics|July 25, 2014
Assessment of tumor growth inhibition metrics to predict overall survivalL Claret, R Bruno
Journal of Molecular Biology|October 25, 1996
Regulation of HU alpha and HU beta by CRP and FIS in Escherichia coliL Claret, J Rouviere-Yaniv
Journal of Molecular Biology|November 21, 1997
Variation in HU composition during growth of Escherichia coli: the heterodimer is required for long term survivalL Claret, J Rouviere-Yaniv
CPT: Pharmacometrics & Systems Pharmacology|December 21, 2016
Model-Based Estimates of Tumor Growth Inhibition Metrics Are Time-Independent: A Reply to MistryL Claret, Kelong Han, R Bruno
Journal of Pharmacokinetics and Pharmacodynamics|January 5, 2002
A stochastic model describes the heterogeneous pharmacokinetics of cyclosporinL Claret, A Iliadis, P Macheras
Clinical Pharmacology and Therapeutics|March 21, 2013
Model-based drug development in oncology: what's next?R Bruno, F Mercier, L Claret
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Mathematical Biosciences|April 1, 1996
Nonparametric density estimation applied to population pharmacokineticsL Claret, A Iliadis
Journal of Molecular Biology|October 31, 2000
Functions of the subunits in the FlhD(2)C(2) transcriptional master regulator of bacterial flagellum biogenesis and swarmingL Claret, C Hughes
Journal of Bacteriology|January 14, 2000
Rapid turnover of FlhD and FlhC, the flagellar regulon transcriptional activator proteins, during Proteus swarmingL Claret, C Hughes
Clinical Pharmacology and Therapeutics|July 22, 2009
On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate phase II studiesR Bruno, L Claret
Clinical Pharmacology and Therapeutics|July 25, 2014
Assessment of tumor growth inhibition metrics to predict overall survivalL Claret, R Bruno
Journal of Molecular Biology|October 25, 1996
Regulation of HU alpha and HU beta by CRP and FIS in Escherichia coliL Claret, J Rouviere-Yaniv
Journal of Molecular Biology|November 21, 1997
Variation in HU composition during growth of Escherichia coli: the heterodimer is required for long term survivalL Claret, J Rouviere-Yaniv
CPT: Pharmacometrics & Systems Pharmacology|December 21, 2016
Model-Based Estimates of Tumor Growth Inhibition Metrics Are Time-Independent: A Reply to MistryL Claret, Kelong Han, R Bruno
Journal of Pharmacokinetics and Pharmacodynamics|January 5, 2002
A stochastic model describes the heterogeneous pharmacokinetics of cyclosporinL Claret, A Iliadis, P Macheras
Clinical Pharmacology and Therapeutics|March 21, 2013
Model-based drug development in oncology: what's next?R Bruno, F Mercier, L Claret
Pageof 3